The data on the kappa AL amyloidosis group treated with anselamimab was presented by AstraZeneca at ASCO 2026. The post ASCO26: AstraZeneca’s light chain amyloidosis shows subgroup benefit after Phase III trial appeared first on Clinical Trials Arena .